Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity - PubMed (original) (raw)

. 2013 Apr 25;439(1):34-41.

doi: 10.1016/j.virol.2013.01.018. Epub 2013 Feb 26.

Sandra V Mayer, Shannan L Rossi, Irma Y Amaya-Larios, Jose Ramos-Castaneda, Eng Eong Ooi, M Jane Cardosa, Jorge L Munoz-Jordan, Robert B Tesh, William B Messer, Scott C Weaver, Nikos Vasilakis

Affiliations

• PMID: 23485373
• PMCID: PMC3622939
• DOI: 10.1016/j.virol.2013.01.018

Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity

Anna P Durbin et al. Virology. 2013.

Abstract

Sylvatic dengue viruses (DENV) are both evolutionarily and ecologically distinct from human DENV and are maintained in an enzootic transmission cycle. Evidence of sylvatic human infections from West Africa and Southeast Asia suggests that sylvatic DENV come into regular contact with humans. Thus, this potential of emergence into the human transmission cycle could limit the potential for eradicating this cycle with vaccines currently in late stages of development. We assessed the likelihood of sylvatic DENV-4 emergence in the face of natural immunity to current human strains and vaccination with two DENV-4 vaccine candidates. Our data indicate homotypic neutralization of sylvatic and human DENV-4 strains by human primary convalescent and vaccinee sera but limited heterotypic immunity. These results suggest that emergence of sylvatic strains into the human cycle would be limited by homotypic immunity mediated by virus neutralizing antibodies produced by natural infection or vaccination.

Copyright © 2013 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Similar articles

• Antigenic relationships between sylvatic and endemic dengue viruses.
  Vasilakis N, Durbin AP, da Rosa AP, Munoz-Jordan JL, Tesh RB, Weaver SC. Vasilakis N, et al. Am J Trop Med Hyg. 2008 Jul;79(1):128-32. Am J Trop Med Hyg. 2008. PMID: 18606776
• [A possible fifth dengue virus serotype].
  da Silva Voorham JM. da Silva Voorham JM. Ned Tijdschr Geneeskd. 2014;158:A7946. Ned Tijdschr Geneeskd. 2014. PMID: 25227888 Dutch.
• Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
  Galula JU, Shen WF, Chuang ST, Chang GJ, Chao DY. Galula JU, et al. J Virol. 2014 Sep;88(18):10813-30. doi: 10.1128/JVI.00810-14. Epub 2014 Jul 9. J Virol. 2014. PMID: 25008922 Free PMC article.
• Immune response to dengue virus and prospects for a vaccine.
  Murphy BR, Whitehead SS. Murphy BR, et al. Annu Rev Immunol. 2011;29:587-619. doi: 10.1146/annurev-immunol-031210-101315. Annu Rev Immunol. 2011. PMID: 21219187 Review.
• Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus.
  Hanley KA, Monath TP, Weaver SC, Rossi SL, Richman RL, Vasilakis N. Hanley KA, et al. Infect Genet Evol. 2013 Oct;19:292-311. doi: 10.1016/j.meegid.2013.03.008. Epub 2013 Mar 20. Infect Genet Evol. 2013. PMID: 23523817 Free PMC article. Review.

Cited by

• Sylvatic dengue virus type 4 in Aedes aegypti and Aedes albopictus mosquitoes in an urban setting in Peninsular Malaysia.
  Johari NA, Voon K, Toh SY, Sulaiman LH, Yap IKS, Lim PKC. Johari NA, et al. PLoS Negl Trop Dis. 2019 Nov 15;13(11):e0007889. doi: 10.1371/journal.pntd.0007889. eCollection 2019 Nov. PLoS Negl Trop Dis. 2019. PMID: 31730672 Free PMC article.
• Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.
  Gallichotte EN, Baric TJ, Nivarthi U, Delacruz MJ, Graham R, Widman DG, Yount BL, Durbin AP, Whitehead SS, de Silva AM, Baric RS. Gallichotte EN, et al. Cell Rep. 2018 Oct 30;25(5):1214-1224. doi: 10.1016/j.celrep.2018.10.006. Cell Rep. 2018. PMID: 30380413 Free PMC article.
• Complex Roles of Neutrophils during Arboviral Infections.
  Muralidharan A, Reid SP. Muralidharan A, et al. Cells. 2021 May 26;10(6):1324. doi: 10.3390/cells10061324. Cells. 2021. PMID: 34073501 Free PMC article. Review.
• Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.
  Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS. Sukupolvi-Petty S, et al. J Virol. 2013 Aug;87(16):8826-42. doi: 10.1128/JVI.01314-13. Epub 2013 Jun 19. J Virol. 2013. PMID: 23785205 Free PMC article.
• Highly divergent dengue virus type 1 genotype sets a new distance record.
  Pyke AT, Moore PR, Taylor CT, Hall-Mendelin S, Cameron JN, Hewitson GR, Pukallus DS, Huang B, Warrilow D, van den Hurk AF. Pyke AT, et al. Sci Rep. 2016 Feb 29;6:22356. doi: 10.1038/srep22356. Sci Rep. 2016. PMID: 26924208 Free PMC article.

References

1. 1. Barban V, Munoz-Jordan JL, Santiago GA, Mantel N, Girerd Y, Gulia S, Claude JB, Lang J. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses. Virology. 2012;429:91–98. - PubMed
2. 1. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, Brandt WE. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. The Journal of general virology. 1989;70(Pt 1):37–43. - PubMed
3. 1. Cardosa J, Ooi MH, Tio PH, Perera D, Holmes EC, Bibi K, Abdul Manap Z. Dengue virus serotype 2 from a sylvatic lineage isolated from a patient with dengue hemorrhagic Fever. PLoS neglected tropical diseases. 2009;3:e423. - PMC - PubMed
4. 1. Carey DE, Causey OR, Reddy S, Cooke AR. Dengue viruses from febrile patients in Nigeria, 1964–68. Lancet. 1971;1:105–106. - PubMed
5. 1. Chen R, Vasilakis N. Dengue - Quo tu et quo vadis? Viruses. 2011;3:1562–1608. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

• 272201000040I/PHS HHS/United States
• T32 AI007536/AI/NIAID NIH HHS/United States
• R01AI069145/AI/NIAID NIH HHS/United States
• R01 AI069145/AI/NIAID NIH HHS/United States
• 272200900010C/PHS HHS/United States
• 2T32AI007536-11A1/AI/NIAID NIH HHS/United States
• U54AI057157/AI/NIAID NIH HHS/United States
• HHSN272201000040I/AI/NIAID NIH HHS/United States
• R01 AI010984/AI/NIAID NIH HHS/United States
• ImNIH/Intramural NIH HHS/United States
• 27200004/D04/PHS HHS/United States
• HHSN272200900010C/AI/NIAID NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information